|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||78.71 - 78.71|
|52-week range||72.98 - 93.58|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||7.72|
|Forward dividend & yield||3.35 (4.32%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||N/A|
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
Whether you're looking for dividends or growth, Novartis and Paramount Global could be viable options for you.